Incyte Corporation (INCY)
Chart Events
Performance Outlook
| Previous Close | 76.06 |
| Open | 73.12 |
| Bid | 70.05 x 800 |
| Ask | 70.05 x 900 |
| Day's Range | 69.82 - 73.85 |
| 52 Week Range | 69.82 - 101.47 |
| Volume | 5,165,801 |
| Avg. Volume | 1,203,148 |
| Market Cap | 15.434B |
| Beta (5Y Monthly) | 0.75 |
| PE Ratio (TTM) | 45.95 |
| EPS (TTM) | 1.52 |
| Earnings Date | Nov 03, 2021 - Nov 08, 2021 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 102.00 |
Fair Value
Related Research
- Incyte CorporationThe Argus Mid-Cap Model PortfolioSmall- and mid-cap stocks (SMID stocks) soared in 2019. They have underperformed large-caps over the past 12 months, but still may be in a better position to generate market-beating returns going forward. For one thing, SMID companies tend to focus on domestic markets, so their businesses could be poised to rebound more quickly once COVID-19 vaccines are more widely distributed and the domestic service economy recovers. As well, the prices of SMID stocks generally are lower than the prices of large-caps. That said, SMID stocks can be risky. Still, despite the risks, diversified investors look to have exposure to small- and mid-caps based on the long-term performance record. Investors used to use a $2 billion market-cap threshold to define a small-cap stock and a $10 billion threshold for a mid-cap. The Russell 2000 index now includes numerous companies with market capitalizations above $15 billion. For our purposes, we use a threshold of $20 billion to define a SMID stock.RatingFair ValueEconomic MoatyesterdayArgus Research
- Business Wire
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
WILMINGTON, Del., September 22, 2021--Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi® (ruxolitinib) for treatment of chronic graft-versus-host disease (GVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
- Motley Fool
Facebook, Incyte Fall Despite the Nasdaq's Strong Wednesday Start
The stock market got off to a strong start on Wednesday, and the Nasdaq Composite (NASDAQINDEX: ^IXIC) benefited from more positive sentiment on Wall Street. As of 10 a.m. EDT, the Nasdaq was up more than half a percent, continuing to claw back some of the ground it lost in Monday's large sell-off. Both Facebook (NASDAQ: FB) and Incyte (NASDAQ: INCY) moved lower on Wednesday morning, reacting to news items that for one of the companies seemed more positive than problematic.
- MarketWatch
Incyte gets FDA approval for atopic dermatitis drug
Shares of Incyte Corp. were down 4.0% in premarket trading on Wednesday, the day after the company announced that the Food and Drug Administration had approved Opzelura as a treatment for some patients with mild to moderate atopic dermatitis. The FDA approval for the topical drug came with a warning for serious adverse events - also referred to a black-box warning - that is consistent with oral JAK inhibitors, according to Mizuho Americas analysts. "Bigger picture, this marks yet another approva
